Advertisement

Impact of 13-valent pneumococcal conjugate polysaccharide vaccination on severe exacerbations in patients with chronic obstructive pulmonary disease and established cardiovascular disease

  • J.M. Figueira Gonçalves
    Correspondence
    Corresponding author at: Camino Margallo 29/4, 38210 San Cristóbal de la Laguna, Santa Cruz de Tenerife, Spain.
    Affiliations
    Pneumology and Thoracic Surgery Service, University Hospital Nuestra Señora de la Candelaria (HUNSC), Santa Cruz de Tenerife, Spain
    Search for articles by this author
  • M.A. García Bello
    Affiliations
    Division of Clinical Epidemiology and Biostatistics, Research Unit, University Hospital Nuestra Señora de la Candelaria (HUNSC) and Primary Care Management, Santa Cruz de Tenerife, Spain
    Search for articles by this author
  • N. Bethencourt Martín
    Affiliations
    Pneumology and Thoracic Surgery Service, University Hospital Nuestra Señora de la Candelaria (HUNSC), Santa Cruz de Tenerife, Spain
    Search for articles by this author
  • D. Díaz Pérez
    Affiliations
    Pneumology and Thoracic Surgery Service, University Hospital Nuestra Señora de la Candelaria (HUNSC), Santa Cruz de Tenerife, Spain
    Search for articles by this author
  • Lina Inmaculada Pérez-Méndez
    Affiliations
    Division of Clinical Epidemiology and Biostatistics, Research Unit, University Hospital Nuestra Señora de la Candelaria (HUNSC) and Primary Care Management, Santa Cruz de Tenerife, Spain

    Networked Biomedical Research Centre (CIBER) of Respiratory Diseases, Carlos III Health Institute, Madrid, Spain
    Search for articles by this author
Published:March 20, 2019DOI:https://doi.org/10.1016/j.ejim.2019.03.010

      Highlights

      • Cardiovascular disease in COPD patients not vaccinated with VNC13 and the exacerbator phenotype are related with the need of hospital admission.
      • VNC13 reduces the risk of hospital admission in non-exacerbator phenotype patients with COPD and established cardiovascular disease.
      • The detected benefit may be related to vaccine-induced immunity and its possible cardioprotective effect.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gonzalez-Romo F.
        • Picazo J.J.
        • Garcia Rojas A.
        • Labrador Hornillo M.
        • Barrios V.
        • Magro M.C.
        • et al.
        Consensus document on pneumococcal vaccination in adults at risk by age and underlying clinical conditions. 2017 update.
        Rev Esp Quimioter. 2017; 30: 142-168
        • Shea K.M.
        • Edelsberg J.
        • Weycker D.
        • Farkouh R.A.
        • Strutton D.R.
        • Pelton S.I.
        Rates of pneumococcal disease in adults with chronic medical conditions.
        Open Forum Infect Dis. 2014; 1ofu024
        • Mannino D.M.
        • Thorn D.
        • Swensen A.
        • Holguin F.
        Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD.
        Eur Respir J. 2008; 32: 962-969
        • Figueira Gonçalves J.M.
        • Bethencourt Martín N.
        • Pérez Méndez L.I.
        • Díaz Pérez D.
        • Guzmán Sáenz C.
        • Viña-Manrique P.
        • et al.
        Impact of 13-valent pneumococal conjugate polysaccharide vaccination in exacerbations rate of COPD patients with moderate to severe obstruction.
        Rev Esp Quimioter. 2017; 30: 269-275
        • Pleguezuelos E.
        • Gimeno-Santos E.
        • Hernández C.
        • Mata M.D.C.
        • Palacios L.
        • Piñera P.
        • et al.
        Recommendations on non-pharmacological treatment in chronic obstructive pulmonary disease from the Spanish COPD guidelines (GesEPOC 2017).
        Arch Bronconeumol. 2018; 54: 568-575
        • Sethi S.
        Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon?.
        Proc Am Thorac Soc. 2004; 1: 109-114
        • Corrales-Medina V.F.
        • Alvarez K.N.
        • Weissfeld L.A.
        • Angus D.C.
        • Chirinos J.A.
        • Choung- Chou H.C.
        • et al.
        Association between hospitalization from pneumonia and subsequent risk of cardiovascular disease.
        JAMA. 2015; 313: 264-274
        • Ren S.
        • Newby D.
        • Li S.C.
        • Walkom E.
        • Miller P.
        • Hure A.
        • et al.
        Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis.
        Open Heart. 2015; 2e000247
        • Binder C.J.
        • Horrko S.
        • Dewan A.
        Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL.
        Nat Med. 2003; 9: 736-743
        • Lamotagne F.
        Pneumococcal vaccination and risk of myocardial infarction.
        CMAJ. 2008; 179: 773-777